Valuation: Chugai Pharmaceutical Co., Ltd.

Market Cap 11,815B 73.9B 66.97B 61.94B 55.89B 105B 6,968B 109B 744B 295B 3,722B 277B 271B P/E 2026 *
23.2x
P/E 2027 * 20.4x
Enterprise Value 10,898B 68.17B 61.77B 57.14B 51.55B 97.15B 6,427B 101B 686B 272B 3,433B 256B 250B EV / Sales 2026 *
7.81x
EV / Sales 2027 * 6.97x
Free-Float
38.12%
Yield 2026 *
1.88%
Yield 2027 * 2.12%
1 day+0.46%
1 week+5.51%
Current month+5.26%
1 month+18.89%
3 months+3.58%
6 months-11.30%
Current year-12.88%
1 week 6,991
Extreme 6991
7,282
1 month 6,269
Extreme 6269
7,381
Current year 5,974
Extreme 5974
10,700
1 year 5,974
Extreme 5974
10,700
3 years 4,572
Extreme 4572
10,700
5 years 3,191
Extreme 3191
10,700
10 years 1,003.33
Extreme 1003.333333
10,700
Manager TitleAgeSince
Chief Executive Officer 63 01/03/2021
Director of Finance/CFO 59 28/03/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 63 01/03/2020
Director/Board Member 59 28/03/2024
Director/Board Member 51 01/03/2025
Change 5-day change 1-year change 3-year change Capi.($)
+0.46%+5.51%-11.49%+52.56% 73.9B
+1.26%+6.61%+40.79%+136.32% 1,286B
+0.79%+3.45%+45.84%+93.52% 688B
+0.20%+1.28%+26.97%+113.70% 521B
-0.44%+3.69%+41.45%+68.91% 386B
+0.55%+0.70%+59.02%+44.62% 364B
-0.12%+0.74%+28.39%+58.54% 302B
+0.37%+0.37%+3.33%+37.27% 287B
-0.30%+1.14%+38.29%+72.46% 252B
+0.08%+0.71%+34.44%+124.95% 208B
Average +0.28%+2.42%+30.70%+80.28% 437B
Weighted average by Cap. +0.54%+3.29%+36.87%+95.76%

Financials

2026 *2027 *
Net sales 1,396B 8.73B 7.91B 7.32B 6.6B 12.44B 823B 12.88B 87.89B 34.85B 440B 32.76B 32.06B 1,527B 9.55B 8.66B 8.01B 7.22B 13.61B 901B 14.09B 96.18B 38.14B 481B 35.85B 35.09B
Net income 510B 3.19B 2.89B 2.67B 2.41B 4.54B 301B 4.7B 32.1B 12.73B 161B 11.96B 11.71B 578B 3.62B 3.28B 3.03B 2.73B 5.15B 341B 5.33B 36.41B 14.44B 182B 13.57B 13.28B
Net Debt -916B -5.73B -5.19B -4.8B -4.33B -8.17B -540B -8.46B -57.72B -22.89B -289B -21.51B -21.05B -1,164B -7.28B -6.6B -6.1B -5.51B -10.38B -686B -10.74B -73.31B -29.07B -367B -27.32B -26.74B
Projected Income Statement - Annual - Chugai Pharmaceutical Co., Ltd.
Logo Chugai Pharmaceutical Co., Ltd.
CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALECENSA, Kadcyla, GAZYVA, CellCept, Zelboraf, Xeloda, Tamiflu, Tarceva, Tecentriq, Herceptin, Perjeta, cancer gene panel testing and others. These products are primarily used to treat conditions such as cancer, kidney disease and kidney transplantation, bone and joint diseases (rheumatoid arthritis), neurological and muscular diseases (neuromyelitis optica spectrum disorders, spinal muscular atrophy, and Duchenne muscular dystrophy), blood disorders (hemophilia and paroxysmal nocturnal hemoglobinuria), and eye diseases (retinal disorders). It also engages in administrative operations, the provision of scientific information on pharmaceuticals, investment activities, and the provision of influenza information services.
Employees
5,104
Date Price Change Volume
13/11/26 JP¥7,181.00 +0.46% 2,047,000
12/11/26 JP¥7,148.00 +0.03% 2,423,700
11/11/26 JP¥7,146.00 -0.22% 3,042,200
10/11/26 JP¥7,162.00 -0.32% 2,455,900
09/11/26 JP¥7,185.00 +5.57% 3,139,300
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Chugai Pharmaceutical Co., Ltd.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
7,181.00JPY
Average target price
8,393.33JPY
Spread / Average Target
+16.88%
  1. Stock Market
  2. Stocks
  3. 4519 Stock